[Report] Monoclonal Therapeutics & Companion Diagnostic Products Market Research, Trends, Analysis TOC

Monoclonal Therapeutics and Companion Diagnostic Products
Chapter 1 - EXECUTIVE SUMMARY
- Summary Table: WORLDWIDE SALES OF MONOCLONAL THERAPEUTIC AND COMPANION DIAGNOSTICS, THROUGH 2012 ($ BILLIONS)
- Summary Figure: WORLDWIDE SALES OF MONOCLONAL THERAPEUTIC AND COMPANION DIAGNOSTICS, 2005-2012 ($ BILLIONS)
  - MAB GROWTH IN THERAPEUTICS
    - PHARMA MOVES IN
- MAB GROWTH IN DIAGNOSTICS
  - KEY DRIVERS AND CHALLENGES
  - SIGNIFICANT TRENDS
Chapter 2 - OVERVIEW
- Table 1 BIOPHARMACEUTICAL CATEGORIES
- Table 2MONOCLONAL ANTIBODIES APPROVED FOR DISEASE THERAPY*
- Table 2 (CONTINUED)
- Figure 1 COMPOSITION OF COMMERCIALIZED ANTIBODIES BY TYPE, 2007 AND 2012 (%)
  - OVERVIEWC(CONTINUED)
- Figure 2 ANTIBODY ILLUSTRATED
  - MAB TECHNOLOGY: BEGINNINGS AND MOVEMENTS
- Table 3TIMELINE FOR MAB DEVELOPMENT
  - MOVING TOWARDS HUMANIZATION
- ANTIBODY TECHNOLOGY TYPES
  - HUMANIZATION
- Table 4 WORLDWIDE FORECAST OF THERAPEUTIC MONOCLONAL ANTIBODIES, BY TYPE, THROUGH 2012 ($ BILLIONS)
  - SUPERHUMANIZATION
  - SMART TECHNOLOGY
- Table 5 SMART TECHNOLOGY ROYALTIES BY LICENSEE AND PRODUCT AS A PERCENTAGE OF TOTAL ROYALTY REVENUE:EXAMPLE OF TECHNOLOGY ROYALTY POTENTIAL (%)
  - FULLY HUMAN TECHNOLOGY
  - PHAGE DISPLAY
    - Phage Display (Continued)
- CRUCELL' S PER.C6 AND MABSTRACT
- TRANSGENIC MICE
- Table 6TRANSGENIC TECHNOLOGIES
- Table 6 (CONTINUED)
  - EMERGING ANTIBODY TECHNOLOGY TYPES
    - Fragments
    - Single Chain Antibodies
    - Bispecific Antibodies
    - Conjugation
- Table 7 LEADING CONJUGATION TECHNOLOGIES
  - TECHNOLOGY RELATED ISSUES AND CHALLENGES
    - Optimization
    - Adjusting Glycosylation
- Table 8ANTIBODY TECHNOLOGY BEHIND COMMERCIALIZED MABS
  - MANUFACTURING
  - LEGALITY AND INTELLECTUAL PROPERTY
    - Legality and Intellectual Property (Continued)
- Table 9 CAT' S PHAGE AND RIBOSOME DISPLAY PATENTS
  - PHARMACEUTICAL AND BIOTECHNOLOGY LANDSCAPE
- Table 10PHARMA' S MAB-RELATED ACQUISITIONS
- Figure 3THE SYNERGY OF PHARMA AND BIOTECH
- Table 11GLOBAL SNAPSHOT: BIOTECHNOLOGY INDUSTRY*
  - Pharmaceutical and Biotechnology ý (Continued)
Chapter 3 - MABS IN THERAPEUTICS
- Figure 4SHARE OF MONOCLONAL ANTIBODY THERAPY MARKET BY THERAPEUTIC AREA, 2007 AND 2012 (%)
- Figure 4 (CONTINUED)
  - SIGNIFICANT TRENDS
  - EXPANDING INDICATIONS
  - NOVEL MECHANISMS OF ACTION
  - NOVEL APPLICATIONS
  - GROUPS OR COMBINATIONS OF ANTIBODIES AND OTHER AGENTS
  - FRAGMENTS OF ANTIBODIES (FABS)
  - COMPANION DIAGNOSTICS
  - MARKETS FOR THERAPEUTIC MABS COMPARED
- Table 12 MARKET VALUE OF BIOPHARMACEUTICAL THERAPEUTIC AREAS, THROUGH 2012 ($ BILLIONS)
- Table 13 WORLDWIDE SALES OF THERAPEUTIC MONOCLONAL ANTIBODIES, BY THERAPEUTIC AREA, THROUGH 2012 ($ BILLIONS)
- Table 14GROWTH OF COMMERCIALIZED MONOCLONAL ANTIBODIES BY THERAPEUTIC AREA, THROUGH 2012 (NUMBER OF COMMERCIALIZED ANTIBODIES EACH YEAR)
- Table 15BIOPHARMACEUTICAL MARKET VALUE OF VARIOUS DISEASES/CONDITIONS, THROUGH 2012 ($ BILLIONS)
  - THERAPEUTIC AREAS DETAILED
  - ONCOLOGY
    - Oncology (Continued)
- ONCOLOGY MARKET AS A WHOLE
- Table 16CANCER' S GLOBAL ANNUAL DEATH TOLL
- Table 17 ESTIMATED NEW CASES OF CANCER IN THE U.S., 2007
  - AIID
  - RESPIRATORY
    - TRANSPLANTATION
    - CENTRAL NERVOUS SYSTEM (CNS)
- Table 18CNS GLOBAL MARKET VALUES ($ BILLIONS)
  - CARDIOVASCULAR (CV)
  - INFECTIOUS DISEASE
  - OPHTHALMOLOGY
  - BLOOD DISORDERS
  - WOMEN' S HEALTH/OSTEOPOROSIS
  - FREQUENT MAB THERAPEUTIC TARGETS
- Table 19COMMON ANTIGEN TARGETS EXPLAINED
- Table 19 (CONTINUED)
- Figure 5MAJOR MAB ANTIGEN TARGETS COMMERCIALIZED
  - THERAPEUTIC MABS IN THE PIPELINE
- Table 20THERAPEUTIC PIPELINE: SELECTED MABS IN DEVELOPMENT
- Table 20 (CONTINUED)
- Table 20 (CONTINUED)
- Table 20 (CONTINUED)
- Table 20 (CONTINUED)
- Table 20 (CONTINUED)
- Table 20 (CONTINUED)
- Table 20 (CONTINUED)
- Table 20 (CONTINUED)
Chapter 4 - MABS IN DIAGNOSTICS
- MABS IN DIAGNOSTICS
- Table 21WORLDWIDE VALUE OF MAB-ASSOCIATED DIAGNOSTICS, BY TECHNOLOGY TYPE, THROUGH 2012 ($ BILLIONS)
  - KEY DRIVERS
    - MABS IN DIAGNOSTIC RADIOPHARMACEUTICALS
      - MAbs in Diagnostic Radiopharmaceuticals (Continued)
- Table 22 SCANNING TECHNOLOGIES THAT ARE USED WITH DIAGNOSTIC RADIOPHARMACEUTICALS
- CHALLENGES FOR MAB DIAGNOSTIC RADIOPHARMACEUTICALS
  - MARKET STATUS
- Table 23MAB-BASED DIAGNOSTIC RADIOPHARMACEUTICALS: CURRENT AND EMERGING
  - FUTURE GROWTH EXPECTED
  - PATHWAYS FORWARD
- MABS IN IMMUNOASSAYS
- Figure 6WORLDWIDE IN-VITRO DIAGNOSTIC MARKET SHARE BY THERAPEUTIC AREA, 2006 (%)
  - IHC AND COMPANION DIAGNOSTICS
  - COMPANY MOVEMENTS
    - Company Movements (Continued)
- REGULATORY PATHMAKING
- EMERGING COMPANION DIAGNOSTIC PRESENCE
A NEW PARADIGM: MULTIFUNCTIONAL MABS IN DEVELOPMENT
- Table 24A NEW PARADIGM: MULTIFUNCTIONAL MAB DEVELOPMENT PIPELINE
- Table 24 (CONTINUED)
Chapter 5 - COMPANY PROFILES
- ABGENIX, INC. (NOW AMGEN)
- ABBOTT LABORATORIES
- Table 25 ABBOTT PRODUCT CATEGORIES
- Table 26 HUMIRA' S LIFECYCLE TO DATE
  - AERES BIOMEDICAL, LTD.
  - ALEXION PHARMACEUTICALS, INC.
    - ALEXION PHARMACEUTICALS, INC. (CONTINUED)
- AMGEN, INC.
- Table 27 AMGEN' S PRODUCTS IN PHASE II OR LATER DEVELOPMENT
  - ARIUS RESEARCH, INC.
  - ASTRAZENECA
- Table 28 ASTRAZENECA' S KEY BIOLOGICALS IN CLINICAL TRIALS
- Table 29 ASTRAZENECA' S KEY BIOLOGICALS IN PRECLINICALS
  - BECKMAN COULTER
  - BIOGEN IDEC, INC.
    - BIOGEN IDEC, INC. (CONTINUED)
    - BIOGEN IDEC, INC. (CONTINUED)
- CAMBRIDGE ANTIBODY TECHNOLOGY, LTD.
- CENTOCOR
  - CHUGAI PHARMACEUTICAL
- Table 30 CHUGAI' S ANTIBODY-BASED PIPELINE
- Table 30 (CONTINUED)
  - CRUCELL
  - CURAGEN CORPORATION
- Table 31 CURAGEN' S ANTIBODY-BASED DRUG CANDIDATES
- Table 31 (CONTINUED)
  - CYTOGEN CORPORATION
  - DYAX CORPORATION
  - ELAN CORPORATION
  - ELAN CORPORATION (CONTINUED)
- EISAI CO., LTD.
- Table 32 EISAI' S (MORPHOTECK ACQUISITION) MONOCLONAL PIPELINE
  - GENENTECH, INC.
    - GENENTECH, INC. (CONTINUD)
- Table 33 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
- Table 34 SELECTED ADDITIONAL PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
  - GENMAB A/S
  - GENZYME CORPORATION
  - GLAXOSMITHKLINE, PLC
    - GLAXOSMITHKLINE, PLC (CONTINUD)
- IMCLONE SYSTEMS
- IMMUNOGEN
- IMMUNOMEDICS, INC.
- Table 35 IMMUNOMEDICS' THERAPEUTIC PRODUCT PIPELINE
  - LONZA BIOLOGICS
  - MEDAREX, INC.
- Table 36 MEDAREX' S PRODUCT PIPELINE
  - MERCK SERONO
  - MICROMET
- Table 37 MICROMET' S PIPELINE
  - MILLENNIUM PHARMACEUTICALS, INC.
- Table 38 MILLENNIUM' S PRODUCTS IN PHASE II OR LATER DEVELOPMENT
  - MORPHOSYS AG
- Table 39 MORPHOSYS HUCAL-BASED ANTIBODY PRODUCTS
- Table 40 MORPHOSYS' PATENT PORTFOLIO
  - NABI PHARMACEUTICALS
  - NOVARTIS PHARMACEUTICALS CORPORATION
  - ORTHO BIOTECH PRODUCTS
  - ONYVAX
  - PDL BIOPHARMA
- Table 41 PDL BIOPHARMA' S PRODUCTS IN PHASE II OR LATER
  - PROGENICS PHARMACEUTICALS
  - REGENERON PHARMACEUTICALS, INC.
  - ROCHE
  - SEATTLE GENETICS
  - TANABE SEIYAKU CO., LTD.
- Table 42 TANABE SEIYAKU' S ANTIBODY-BASED PIPELINE
  - UCB S.A.
  - VIVALIS
  - VIVENTIA BIOTECH, INC.
  - WYETH PHARMACEUTICALS, INC.
  - XOMA, LTD.

Monoclonal Therapeutics and Companion Diagnostic Products

Table of Contents